These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37833617)

  • 21. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
    De Greef A; Thirion R; Ghislain PD; Baeck M
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
    Taylor S; Korman NJ; Tsai TF; Shimomura Y; Feely M; Dutronc Y; Wu WS; Somani N; Tosti A
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3181-3191. PubMed ID: 37740856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baricitinib as the first systemic treatment for severe alopecia areata.
    Kincaid CM; Arnold JD; Mesinkovska NA
    Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
    Dillon KL
    Clin Cosmet Investig Dermatol; 2021; 14():691-714. PubMed ID: 34211288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
    JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
    [No Abstract]   [Full Text] [Related]  

  • 29. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
    Kołcz K; Żychowska M; Sawińska E; Reich A
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
    King B; Senna MM; Mesinkovska NA; Lynde C; Zirwas M; Maari C; Prajapati VH; Sapra S; Brzewski P; Osman L; Hanna S; Wiseman MC; Hamilton C; Cassella J
    J Am Acad Dermatol; 2024 Jul; ():. PubMed ID: 39053611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
    King B; Mesinkovska N; Mirmirani P; Bruce S; Kempers S; Guttman-Yassky E; Roberts JL; McMichael A; Colavincenzo M; Hamilton C; Braman V; Cassella JV
    J Am Acad Dermatol; 2022 Aug; 87(2):306-313. PubMed ID: 35364216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
    Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
    EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    King B; Ko J; Kwon O; Vañó-Galván S; Piraccini BM; Dutronc Y; Yu G; Liu C; Somani N; Ball S; Mesinkovska NA
    JAMA Dermatol; 2024 Aug; ():. PubMed ID: 39141364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel investigational drugs for alopecia areata and future perspectives.
    Chim I; Ghiya R; Sinclair RD; Eisman S
    Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for the treatment of alopecia areata.
    Ramírez-Marín HA; Tosti A
    Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
    Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
    Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.